Trial Profile
Phase I Study of Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 19 Jul 2018
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary) ; Bevacizumab
- Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
- Focus Adverse reactions
- 25 Jun 2018 Results (n=26) published in the Clinical Cancer Research.
- 21 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Jan 2017.
- 29 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016, according to ClinicalTrials.gov record.